Larotrectinib

Chemical formula: C₂₁H₂₂F₂N₆O₂  Molecular mass: 428.444 g/mol 

Active ingredient description

Larotrectinib is an adenosine triphosphate (ATP)-competitive and selective tropomyosin receptor kinase (TRK) inhibitor. The TRK family of proteins, TRKA, TRKB, and TRKC, is encoded by NTRK1, NTRK2 and NTRK3 genes. Larotrectinib was rationally designed to avoid activity with off-target kinases. It is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
L01EX12 L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX12

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
VITRAKVI Oral solution European Medicines Agency (EU) MPI, EU: SmPC
VITRAKVI Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
VITRAKVI Capsule / Oral solution FDA, National Drug Code (US) MPI, US: SPL/PLR

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 1223403-58-4
DrugBank Drug: DB14723
RxNorm Ingredient: 2105628
SNOMED-CT Concept: 782977003
Larotrectinib (substance)
UNII Identifier: PF9462I9HX
LAROTRECTINIB

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.